Eli Lilly and Company (LLY) News Today

Eli Lilly and Company (NYSE: LLY) shares have decreased as investors balance positive pipeline and product news against the cost and early-stage risk of a major acquisition, broader healthcare-sector weakness, and intensifying competition in obesity drugs.

• Positive Sentiment: Mounjaro’s expanded FDA approval supports growth. The FDA authorized Mounjaro (tirzepatide) to reduce cardiovascular risk in high-risk adults with type 2 diabetes, broadening the drug’s addressable market and potential commercial opportunity. Mounjaro FDA approval article
• Positive Sentiment: New data strengthen the Zepbound and Taltz opportunity. Lilly reported that combining Zepbound with Taltz produced durable improvements after one year in adults with psoriasis or psoriatic arthritis and obesity. The findings could support broader use of the medicines together, although they came from Phase 3b studies rather than a new approval. Taltz and Zepbound Phase 3b data
• Neutral Sentiment: The Merida Biosciences acquisition expands Lilly’s immunology pipeline but carries execution risk. Lilly agreed to acquire Merida for up to $2.875 billion in cash, including milestone payments, with closing expected in the fourth quarter of 2026. Merida’s platform targets autoimmune and allergic diseases, while lead candidate MER511 has shown early reductions in thyroid-stimulating antibodies. However, the program remains in Phase 1, so meaningful revenue is distant and clinical risk remains high. Merida acquisition announcement
• Neutral Sentiment: Low-dose GLP-1 findings are mixed for Lilly. A study suggested that patients remaining on starter doses can lose weight with less nausea, potentially improving tolerability and adherence, but lower doses may deliver less weight loss than recommended maintenance doses. GLP-1 starter-dose study
• Negative Sentiment: Acquisition spending and competitive concerns weigh on sentiment. Investors may question Lilly’s growing dealmaking outlays, particularly because Merida’s lead asset is early stage. Separately, Amylyx and other developers are reporting progress on competing GLP-1 candidates, raising longer-term concerns around Lilly’s dependence on Mounjaro and Zepbound. Healthcare-sector weakness also added to the pressure.